CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Renal Cell ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps4579 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4579-TPS4579 ◽

Cited By ~ 1

Author(s):

Martin Henner Voss ◽

Andrea Coates ◽

Edward Graeme Garmey ◽

Naomi B. Haas ◽

Thomas Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Standard Of Care ◽

Phase 2 ◽

Safety And Efficacy ◽

Phase 2 Study ◽

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

European Urology ◽

10.1016/j.eururo.2021.01.003 ◽

2021 ◽

Author(s):

Thomas Powles ◽

Michael B. Atkins ◽

Bernard Escudier ◽

Robert J. Motzer ◽

Brian I. Rini ◽

...

Keyword(s):

Clinical Trial ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Disease Progression ◽

Renal Cell ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Clinical Trial ◽

Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study

European Urology Supplements ◽

10.1016/s1569-9056(19)34691-3 ◽

2019 ◽

Vol 18 (11) ◽

pp. e3552

Author(s):

G. Procopio ◽

G. Apollonio ◽

F. Cognetti ◽

R. Miceli ◽

M. Milella ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Clinical Outcome ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Study ◽

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2016.02.007 ◽

2016 ◽

Vol 14 (4) ◽

pp. 304-313.e6 ◽

Cited By ~ 9

Author(s):

Kathleen M. Mahoney ◽

Susanna Jacobus ◽

Rupal S. Bhatt ◽

Jiaxi Song ◽

Ingrid Carvo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Study

7140 POSTER A Randomized Phase 2 Study of Axitinib Dose Titration in Patients With Advanced Renal Cell Carcinoma (RCC): Preliminary Pharmacokinetic and Ambulatory Blood Pressure (BP) Monitoring Results

European Journal of Cancer ◽

10.1016/s0959-8049(11)72055-x ◽

2011 ◽

Vol 47 ◽

pp. S517

Author(s):

V. Grunwald ◽

M.N. Fishman ◽

T.E. Hutson ◽

A. Bair ◽

Y. Chen ◽

...

Keyword(s):

Blood Pressure ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Ambulatory Blood Pressure ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Dose Titration ◽

Phase 2 ◽

Phase 2 Study ◽

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30513-3 ◽

2019 ◽

Vol 20 (10) ◽

pp. 1386-1394 ◽

Cited By ~ 23

Author(s):

Moshe C Ornstein ◽

Sumanta K Pal ◽

Laura S Wood ◽

Jackie M Tomer ◽

Brian P Hobbs ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Checkpoint Inhibitors ◽

Phase 2 ◽

Phase 2 Study

Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma

BJU International ◽

10.1111/bju.15058 ◽

2020 ◽

Vol 126 (1) ◽

pp. 73-82 ◽

Cited By ~ 2

Author(s):

Sumanta K. Pal ◽

David F. McDermott ◽

Michael B. Atkins ◽

Bernard Escudier ◽

Brian I. Rini ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Patient Reported Outcomes ◽

Phase 2 ◽

Phase 2 Study ◽

Patient Reported

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

Annals of Oncology ◽

10.1093/annonc/mdw676 ◽

2017 ◽

Vol 28 (4) ◽

pp. 804-808 ◽

Cited By ~ 17

Author(s):

E. Jonasch ◽

E. Hasanov ◽

P.G. Corn ◽

T. Moss ◽

K.R. Shaw ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Study ◽

TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Annals of Oncology ◽

10.1093/annonc/mdw373.78 ◽

2016 ◽

Vol 27 ◽

pp. vi295

Author(s):

T. Choueiri ◽

N. Agarwal ◽

T. Ho ◽

S.K. Pal ◽

B. Seon ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy

European Journal of Cancer ◽

10.1016/s0959-8049(16)30266-0 ◽

2015 ◽

Vol 51 ◽

pp. S89 ◽

Cited By ~ 1

Author(s):

H. Glen ◽

J. Hsieh ◽

M.D. Michaelson ◽

H.J. Kim ◽

P. Sachdev ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Clinical Outcomes ◽

Renal Cell ◽

Serum Biomarkers ◽

Phase 2 ◽

Phase 2 Study